In the latest study and trials conducted in patients, the effectiveness of therapy in a type of hematologic cancer is validated.
CAR-T therapy benefits in multiple myeloma.
And it is the clinical trials and studies to increase the quality of life of patients with Cancer han dado sus frutos. Recently, a CAR-T investigation was conducted to help Jamie Atkinson, who volunteered as he states: “This is the ultimate remedy that needs to improve my prognosis.”
The diagnosis of hematologic disease was made by surprise at Atkinson four years ago and there were no symptoms of the disease or evidence that powder indicates that the pathology is serious.
I wish I had received the red and white globes and I was suddenly shocked and referred to a hematologist who told me the news. “It’s initial symptoms, thanks to God’s diagnosing and treating me,” Atkinson assured.
El patient make sure that no one passes by any feeling of sadness that he is more than happy, and that only he has a good life and is the father of three he who has exits in one of his professional inclinations, only he wants a new step with his wife , but the disease limits some plans, but it does show that it has some sense of frustration.
Respecto a su vida professional el patient society of a company always stems from this and continues in this laborious aspect with normality and its focus in recovery was an angle to follow adelante, giving two sessions of chemotherapy and a transplant of whole cells, without embarrassment, in the state empeoró of 2019.
The transplant of cells will work for 10 months and will be in complete remission for a while, and the wine will be ready for recovery “, dijo el patient.
Therapy CAR-T
“The hope is that this treatment may be approved for its own use during the course of illness,” said Dra. Melissa Alsina, Department of Cellular Immunotherapy in Transplant of Sangre and Medium Ocean.
Atkinson is part of a Phase 2 studio set up by Dra. Alsina, however, the same is directed at the use of an immunotherapy with cells T with CAR that consist of attacking cells B that can have no incidence in the manifestation of multiple myeloma. This assay is created with the finality of the efficiency and security of the therapy CAR T in those patients he presented received or who did not respond to determined treatments.
“The hope is that this treatment may be approved for its use in the course of the nurse and that the additional investigation can improve the results of the approval of this product by the FDA,” said Alsina.
As Atkinson affirma gracias al studio al que fue sometido desel de 6 de enero del año pasade, su prognostico y estado de salud se haveste favoret yad que ha podido retarun algun activities en labores que la enfermedad limo, sostiene que existen algunos sintomas per que you can play with them, you are very happy with the Dra. Alsina can make sure that the salvo is alive.